Gilead SciencesGILDEarnings & Financial Report
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
GILD Q3 2025 Key Financial Metrics
营收
$7.8B
毛利润
$6.2B
营业利润
$3.3B
净利润
$3.1B
毛利率
79.8%
营业利润率
42.8%
净利率
39.3%
同比增长
3.0%
EPS
$2.43
资金流向
Gilead Sciences Q3 2025 Financial Summary
Gilead Sciences reported revenue of $7.8B for Q3 2025, with a net profit of $3.1B (39.3% margin). Cost of goods sold was $1.6B, operating expenses totaled $2.9B.
Key Financial Metrics
| Total Revenue | $7.8B |
|---|---|
| Net Profit | $3.1B |
| Gross Margin | 79.8% |
| Operating Margin | 42.8% |
| Report Period | Q3 2025 |
Gilead Sciences Annual Revenue by Year
Gilead Sciences annual revenue history includes year-by-year totals (for example, 2024 revenue was $28.8B).
| Year | Annual Revenue |
|---|---|
| 2024 | $28.8B |
| 2023 | $27.1B |
| 2022 | $27.3B |
利润表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $7.11B | $6.69B | $6.95B | $7.54B | $7.57B | $6.67B | $7.08B | $7.77B |
| 同比增长 | -3.7% | 5.3% | 5.4% | 7.0% | 6.4% | -0.3% | 1.8% | 3.0% |
资产负债表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $62.13B | $56.29B | $53.58B | $54.52B | $58.99B | $56.43B | $55.72B | $58.53B |
| 总负债 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| 股东权益 | $22.83B | $17.54B | $18.28B | $18.48B | $19.33B | $19.16B | $19.67B | $21.54B |
现金流量表
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $2.17B | $2.22B | $1.32B | $4.31B | $2.98B | $1.76B | $827.0M | $4.11B |
Other Health Care Companies
ABBV
AbbVie
营收
$15.8B
净利润
$186.0M
AMGN
Amgen
营收
$9.9B
净利润
$1.3B
BIIB
Biogen
营收
$2.3B
净利润
$-48.9M
INCY
Incyte
营收
$1.5B
净利润
$299.3M
MRNA
Moderna
营收
$1.0B
净利润
$-200.0M
REGN
Regeneron Pharmaceuticals
营收
$3.9B
净利润
$844.6M
VRTX
Vertex Pharmaceuticals
营收
$3.2B
净利润
$1.2B
ABT
Abbott Laboratories
营收
$11.4B
净利润
$1.6B
A
Agilent Technologies
营收
$1.9B
净利润
$434.0M
ALGN
Align Technology
营收
$995.7M
净利润
$56.8M